

# Multidisciplinary insights on the role of GLP-1 RAs in the modern management of stroke in patients with T2D

# Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*

# Expert panel



**Prof. Tina Vilsbøll**

Clinical Professor, Steno  
Diabetes Center Copenhagen  
and University of  
Copenhagen, Denmark



**Dr Yassir Javaid**

Cardiovascular and  
Diabetes Lead, Nene CCG,  
Northamptonshire, UK



**Prof. Georgios K Tsivgoulis**


Professor & Chairman of Second  
Department of Neurology,  
National and Kapodistrian  
University of Athens, Greece



**Ms Hyvelle Ferguson-Davis**

Patient advocate, stroke survivor  
and person living with T2D,  
Florida, USA


# Evidence of GLP-1 RAs reducing incidence of stroke in T2D (1/2)



GLP-1 RA; glucagon-like peptide-1 receptor agonist; HR, hazard ratio; MI, myocardial infarction; PBO, placebo; SC, subcutaneous; TIA, transient ischaemic attack; T2D, type 2 diabetes.  
 1. Gerstein HC, et al. *Lancet*. 2019;394:121–30; 2. Gerstein HC, et al. *Lancet Diabetes Endocrinol*. 2020;8:106–14; 3. Marso SP, et al. *N Engl J Med*. 2016;375:1834–44; 4. Leiter LA, et al. *Cardiovasc Diabetol*. 2019;18:73; 5. Strain WD, et al. *Stroke*. 2022;53:2749–57.

# Evidence of GLP-1 RAs reducing incidence of stroke in T2D (2/2)


Meta-analyses



CVOT, cardiovascular outcomes trial; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HR, hazard ratio; MI, myocardial infarction; OR, odds ratio; PBO, placebo; RCT, randomized controlled trial; T2D, type 2 diabetes.

1. Bellastella G, et al. *Stroke*. 2020;51:666–9; 2. Malhotra K, et al. *J Neurol*. 2020;26:2117–22; 3. Giugliano D, et al. *Cardiovasc Diabetol*. 2021;20:189.

# Guideline recommendations for the use of GLP-1 RAs for the management of stroke in patients with T2D



ADA, American Diabetes Association; AHA, American Heart Association; ASA, American Stroke Association; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DCRM, diabetes, cardiorenal and/or metabolic disease; ESC, European Society of Cardiology; ESO, European Stroke Organisation; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; TIA, transient ischaemic attack.

1. Davis MJ, et al. *Diabetologia*. 2022;doi: 10.1007/s00125-022-05787-2; 2. Kleindorfer DO, et al. *Stroke*. 2021;52:e364–467; 3. Visseren FLJ, et al. *Eur Heart J*. 2021;42:3227–337;

4. Dawson J, et al. *Eur Stroke J*. 2022;7:1–11; 5. Handelsman Y, et al. *J Diabetes Complications*. 2022;26:108101.